A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-23

Study Completion Date

2012-03-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

NCT00603356

Advanced Solid Tumors

COMPLETED PHASE1

Study of Continuous OSI-906 Dosing

NCT00514007

Advanced Solid Tumors

COMPLETED PHASE1

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851

Advanced Solid Tumors

COMPLETED PHASE1

Study of Intermittent OSI-906 Dosing

NCT00514306

Advanced Solid Tumors

COMPLETED PHASE1

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

NCT00975182

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will open with Schedule 1 (S1), in which OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2. A treatment period is defined as 21 days.

Initiation of Schedule 2 (S2), in which OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity \>/= grade 2 in any patient on S1 or after \> 2 dose levels in S1 have been examined without evidence of Dose Limiting Toxicities (DLT).

Initiation of Schedule 3 (S3), in which OSI-906 is administered twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2, will occur after observation of clinically significant related toxicity \>/= grade 2 in any patient on S2 or after \> 2 dose levels in S2 have been examined without evidence of DLT.

Once the phase 2 dose has been established for S3, 1 expansion cohort will be opened.

The Expansion Cohort will enroll approximately 30 evaluable patients with stage IIIB/IV Non-small Cell Lung Carcinoma (NSCLC). Patients in the NSCLC Expansion Cohort will be required to have either archival tissue or fresh tumor tissue available at the start of study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Schedule 1

OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.

Group Type EXPERIMENTAL

OSI-906

Intervention Type DRUG

administered orally

erlotinib

Intervention Type DRUG

administered orally

Schedule 2

OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.

Group Type EXPERIMENTAL

OSI-906

Intervention Type DRUG

administered orally

erlotinib

Intervention Type DRUG

administered orally

Schedule 3

OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.

Group Type EXPERIMENTAL

OSI-906

Intervention Type DRUG

administered orally

erlotinib

Intervention Type DRUG

administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OSI-906

administered orally

Intervention Type DRUG

erlotinib

administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tarceva OSI-774

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed advanced solid tumor
* For the NSCLC Expansion Cohort, a confirmed diagnosis of stage IIIB/IV NSCLC after failure of at least 1 prior chemotherapy regimen is required
* Patients with Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
* Predicted life expectancy \>/= 12 weeks
* Patients may have had prior therapy, providing certain conditions are met:

1. Chemotherapy: A minimum of 3 weeks (4 weeks for carboplatin or investigational anticancer agents and 6 weeks for nitrosoureas and mitomycin C) must have elapsed between the end of treatment and registration into this study. Patients must have recovered from any treatment-related toxicities (except for alopecia, fatigue, and grade 1 neurotoxicity) prior to registration.
2. Hormonal therapy: Patients may have had prior anticancer hormonal therapy provided it is discontinued prior to registration into the study. However, patients with prostate cancer with evidence of progressive disease may continue on therapy that produces medical castration (eg, goserelin or leuprorelin), provided this therapy was commenced at least 3 months earlier.
3. Radiation: Patients may have had prior radiation therapy provided they have recovered from the acute, toxic effects of radiotherapy prior to registration. A minimum of 21 days must have elapsed between the end of radiotherapy and registration into the study unless the radiation affected less than 25% of bone marrow.
4. Surgery: Previous surgery is permitted provided that wound healing has occurred prior to registration.
* Fasting glucose \</= 125 mg/dL (7 mmol/L) at baseline and on Day 1 prior to dosing
* Blood ketones \</= Upper Limit of Normal (ULN)
* Neutrophil count \>/= 1.5 x 10\^9/L
* Platelets \>/= 100 x 10\^9/L
* Bilirubin \</= 1.5 x ULN
* AST and/or ALT \</= 2.5 x ULN or \</= 5 x ULN if patient has documented liver metastases
* Serum creatinine \</= 1.5 x ULN
* Patients must be nonsmokers (or former smokers who stopped smoking \> 3 months previously) and have a negative cotinine test at baseline and on Day 1
* Patients in the NSCLC Expansion Cohort must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
* Patients in the NSCLC Expansion Cohort will be required to have either an archival or fresh tumor tissue (whole or partial block) available at the start of study
* Patients must be accessible for repeat dosing and follow-up, including pharmacokinetic sampling
* Patients - both males and females - with reproductive potential must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test at baseline and on Day 1
* Patients must provide verbal and written informed consent to participate in the study

Exclusion Criteria

* Documented history of diabetes mellitus
* History of significant cardiac disease unless the disease is well-controlled. Significant cardiac diseases includes second/third degree heart block; significant ischemic heart disease; QTc interval \> 450 msec at baseline; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)
* History of cerebrovascular accident (CVA) within 12 months prior to registration or that is not stable
* Prior epidermal growth factor receptor (EGFR) or insulin like growth factor receptor (IGFR) inhibitor therapy, except for prior erlotinib therapy in the NSCLC Expansion Cohort, prior erlotinib therapy will not be exclusionary
* History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
* Pregnant or breast-feeding females
* Gastrointestinal (GI) abnormalities including inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer, or prior surgical procedures affecting absorption
* Ocular inflammatory or infectious condition that is not completely resolved prior to registration
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
* Any type of active seizure disorder
* Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing
* Use of strong or moderate CYP3A4 or CYP1A2 inhibitors/inducers, with the exception of low-dose steroids, within 14 days prior to Day 1 dosing
* Use of proton pump inhibitors within 14 days prior to day 1 dosing
* Symptomatic brain metastases that are not stable, require steroids, or that have required radiation within the last 28 days
* Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No